Patents Examined by Magdalene K. Sgagias
  • Patent number: 10779519
    Abstract: The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 22, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Steven A. Goldman, Martha Windrem
  • Patent number: 10752915
    Abstract: In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 25, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
  • Patent number: 10745668
    Abstract: Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stem cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMP). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stem cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of disease amendable to treatment by stem cell therapy; as well as kits for such uses.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 18, 2020
    Assignee: LONZA LTD
    Inventors: Patrick Walsh, Thomas Fellner
  • Patent number: 10731134
    Abstract: It is intended to provide a cancer stem cell and a method for preparing the same. The present invention provides a method for preparing a pluripotent cancer stem cell, comprising transferring Oct3/4, Sox2, Klf4, and c-Myc genes to an immortalized epithelial cell. The present invention also provides a pluripotent cancer stem cell as prepared by the above method.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 4, 2020
    Assignee: Public University Corporation Yokohama City University
    Inventors: Akihide Ryo, Mayuko Nishi
  • Patent number: 10709120
    Abstract: A nonhuman animal cancer model is described. The animal model includes an animal of the genus Peromyscus and xenograft cancer cells implanted in the animal. Methods for utilizing the animal model can include evaluation of growth and development of cancer cells as well as evaluation of known and potential cancer treatment therapies. The animal model can be utilized to examine the efficacy of an anticancer therapy at the preclinical stage, can be utilized to screen potential cancer treatments in an individualized cancer treatment protocol, and can be utilized for identification of biomarkers associated with particular cancers and/or particular anticancer therapies, among other beneficial uses.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 14, 2020
    Assignee: University of South Carolina
    Inventors: Vimala Kaza, Eleni Farmaki, Ioulia Chatzistamou, Hippokratis Kiaris
  • Patent number: 10655100
    Abstract: The present invention relates to a method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation, and more particularly, to a method of promoting the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by stimulating and activating the surface receptor CXCR2 of the embryoid bodies with the CXCR2-specific ligand GRO-?. The method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation according to the present invention can increase the efficiency and utility of stem cells as a cell therapeutic agent, because it promotes the differentiation of stem cells into a specific germ layer serving as the origin of target cells, which is the first important step for inducing the differentiation of stem cells into specific cells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Byung Soo Kim, Ji-Hye Jung, Yong Park
  • Patent number: 10640800
    Abstract: Provided herein is a mouse that produces hybrid antibodies containing human variable regions and mouse constant regions.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 5, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn MacDonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Patent number: 10617771
    Abstract: The present invention provides new Adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type II.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 14, 2020
    Assignees: UNIVERSITAT AUTÓNOMA DE BARCELONA, ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Maria Fàtima Bosch Tubert, Virginia Areba Haurigot, Sandra Motas Mallol
  • Patent number: 10604738
    Abstract: This invention relates to the forward programming of pluripotent stem cells (PSCs) into megakaryocyte (MK) progenitor cells using the transcription factors GATA1, FLI1 and TAL1. Methods of producing megakaryocyte (MK) progenitor cells and subsequently differentiating them into mature megakaryocytes are provided.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 31, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Roger Pedersen, Willem Ouwehand, Thomas Moreau, Cedric Ghevaert, Matthew Trotter
  • Patent number: 10603407
    Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: March 31, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Abdulhafez A. Selim, Lawrence A. Shimp, Hsiu Ying Sherry Wang
  • Patent number: 10480031
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 19, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kapil Bharti, Janine Davis
  • Patent number: 10457915
    Abstract: The present invention is based in part on a chemically defined method of generating retinal epithelial cells and retinal pigmented epithelial cells from human pluripotent stem cells (hpSCs). The present invention also provides methods and kits for treating degenerative eye disorders.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 29, 2019
    Assignee: International Stem Cell Corporation
    Inventors: Russell A. Kern, Rodolfo Gonzalez
  • Patent number: 10444227
    Abstract: In some aspects, cultures of neurons derived from human induced pluripotent stem cells (iPS cells) that exhibit synchronous firing of neural networks are provided. In some embodiments, neuronal activity of the cultures may be detected or measured using a multi-electrode array.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: October 15, 2019
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Kile P. Mangan, Coby B. Carlson
  • Patent number: 10429378
    Abstract: Described herein are methods of transdifferentiating preadipocytes, populations of transdifferentiated preadipocytes, and methods of using the transdifferentiated preadipocytes.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: October 1, 2019
    Assignee: Board Of Supervisors Of Louisiana State University
    Inventors: Kenneth James Eilertsen, Jong Rim
  • Patent number: 10426844
    Abstract: Disclosed are capsid-mutated rAAV vectors and methods for their use in gene therapy, and particularly for use in delivering therapeutic transgenes to treat a variety of mammalian diseases and disorders, including dysfunctions and abnormal conditions of the human eye. VP3 capsid proteins comprising a modification of one or more of the surface-exposed tyrosine residues are disclosed, and in particular, VP3 capsid protein comprising tyrosine-to-phenylalanine mutations at positions corresponding to Y444F, Y500F, and Y730F of the wild-type AAV2 sequence. Also provided are rAAV virions and viral particles that comprise such a mutated AAV capsid protein and a nucleic acid molecule that expresses one or more selected therapeutic or reporter transgenes in one or more mammalian cells of interest. Advantageously, the capsid-mutated rAAV vectors and virions disclosed herein afford improved transduction efficiency in a variety of cells, tissues and organs of interest, when compared to their unmodified (i.e.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 1, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Mavis Agbandje-McKenna, William W. Hauswirth, Arun Srivastava, Li Zhong
  • Patent number: 10415056
    Abstract: In one aspect, the present invention provides an intron-modified cap expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 17, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
  • Patent number: 10369196
    Abstract: Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 6, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Yael Cohen, Livnat Bangio, Andrew J. Brenner, Eyal Breitbart
  • Patent number: 10308705
    Abstract: The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing modifications in the amino acid sequence of the Factor VIII protein, as well as nucleic acid constructs encoding the Factor VIII proteins and methods of using these compositions to treat a bleeding disorder.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 4, 2019
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xiao Xiao, Juan Li, Zhenhua Yuan
  • Patent number: 10280436
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: May 7, 2019
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Patent number: 10227625
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: March 12, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela